TEPEZZA — Total revenues
Products & Services · Total revenuesAmgen TEPEZZA — Total revenues remained flat by 0.0% to $475.75M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 2.8%, from $462.75M to $475.75M. Over 2 years (FY 2023 to FY 2025), TEPEZZA — Total revenues shows an upward trend with a 106.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market penetration or successful clinical adoption of the therapy, while a decrease may signal increased competition, patent expiration, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total gross revenue generated from the sales of a specific therapeutic product line within th...
Peer comparison
Comparable to product-specific revenue reporting for flagship therapeutics at other large-cap biotechnology and pharmaceutical companies.
amgn_segment_tepezza_total_revenuesHistorical Data
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $448.00M | $1.85B | $1.90B |
| YoY Change | — | +313.2% | +2.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's tepezza — total revenues?
- Amgen (AMGN) reported tepezza — total revenues of $475.75M in Q4 2025.
- How has Amgen's tepezza — total revenues changed year-over-year?
- Amgen's tepezza — total revenues increased by 2.8% year-over-year, from $462.75M to $475.75M.
- What is the long-term trend for Amgen's tepezza — total revenues?
- Over 2 years (2023 to 2025), Amgen's tepezza — total revenues has grown at a 106.1% compound annual growth rate (CAGR), from $448.00M to $1.90B.
- What does tepezza — total revenues mean?
- The total sales revenue generated by a specific therapeutic product line.